Sexually transmitted infections (STIs) are on the rise for the 6th year in a row, yet many STIs are undetected as people often do not have symptoms.1,2 Patients with asymptomatic infections do not seek testing, leading to increased transmission and complications in females, yet screening rates remain low.3
Americans have an STI1,4*
*On any given day in 2018.
Universal screening with opt-out can help ensure that your female patients ages 15-24 can be identified and treated, thereby reducing their risk of developing pelvic inflammatory disease and ultimately protecting their fertility.
females each year become infertile due to untreated STIs that lead to pelvic inflammatory disease (PID)5,6
Notify ALL female patients ages 15-24 that CT/NG screening is included in their annual visits unless specifically declined8
As of 2018, 1 in 2 STIs was acquired by people under the age 254
More than half of females ages 15–24 are reluctant to bring up STIs with their provider9
Most female patients <25 years of age want their doctors to automatically test them for CT and NG once a year10
From the 2021 CDC Guidelines8
When the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity, this is known as ‘opt-out screening.’ Providers might consider opt-out chlamydia and gonorrhea screening for adolescent and young adult females during clinical encounters.
Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might:
• Substantially increase screening
• Be cost-saving
• Identify infections among patients who do not disclose sexual behavior
Universal screening with opt-out can be integrated into OBGYN practices without disrupting the practice workflow. By increasing screening, you can help ensure that your at-risk patients can be identified and treated earlier—reducing their risk of developing PID and ultimately protecting their fertility.
Eases pressure on providers to identify sexual activity among adolescent and young adult patients
May help patients feel less judged or singled out
Can help in conversations with parents who think their child may have been screened due to risk
Is usually available to patients at $0 copay12
As part of mandatory reporting requirements to identify potential abuse, when testing minors under the age of consent, healthcare professionals may be required in certain jurisdictions to report positive results of sexually transmitted disease testing to authorities.
in your female patients—and screening accordingly.
Both the Centers for Disease Control and Prevention (CDC) and US Preventive Services Task Force (USPSTF) recommended screening for chlamydia and gonorrhea in sexually active women ages 25 and older if at increased risk for infection.8,13 Trichomonas screening should also be considered.
Do you use condoms: never, sometimes, or always?
In the past 12 months, how many partners have you had sex with?
Have you ever had an STI?
Has a partner had an STI?
Contact your Quest Diagnostics representative about how you can make universal screening with opt-out the standard of care in your practice.Contact Us
Screening for STIs is recommended for women at all stages of their lives. The intuitive tables below can help guide your discussions for patient-focused testing recommendations.
a People with increased risk are women who have had a history of sexually transmitted diseases (STDs), exchange sex for payment, or use injection drugs; and men and women with a new sex partner, more than 1 sex partner, a sex partner with concurrent partners, or a sex partner who has a sexually transmitted infection.
b When highly sensitive testing (eg, nucleic acid amplification test [NAAT]) is not feasible, a testing algorithm (eg, wet mount first, followed by NAAT if negative) can improve diagnostic sensitivity.
c The use of chlamydial NAATs at <3 weeks after completion of therapy is not recommended because the continued presence of nonviable organisms can lead to false-positive results.9
Test codes may vary by location. Please contact your local laboratory for more information.